Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $305,976 - $436,012
-7,600 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$54.88 - $79.29 $1.66 Million - $2.4 Million
-30,319 Reduced 79.96%
7,600 $432,000
Q1 2021

May 14, 2021

SELL
$70.65 - $96.76 $6.31 Million - $8.64 Million
-89,276 Reduced 70.19%
37,919 $2.84 Million
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $127,450 - $194,328
-2,182 Reduced 1.69%
127,195 $11 Million
Q3 2020

Nov 13, 2020

SELL
$41.13 - $62.45 $3.86 Million - $5.86 Million
-93,895 Reduced 42.05%
129,377 $7.91 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $4.64 Million - $7.72 Million
178,821 Added 402.29%
223,272 $9.28 Million
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $73,899 - $218,280
-2,826 Reduced 5.98%
44,451 $1.28 Million
Q4 2019

Feb 18, 2020

BUY
$60.18 - $154.77 $64,994 - $167,151
1,080 Added 2.34%
47,277 $3.41 Million
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $11,503 - $15,576
-82 Reduced 0.18%
46,197 $6.48 Million
Q2 2019

Aug 13, 2019

BUY
$157.85 - $183.09 $159,270 - $184,737
1,009 Added 2.23%
46,279 $8.47 Million
Q4 2018

Feb 13, 2019

SELL
$81.94 - $139.71 $1.99 Million - $3.39 Million
-24,300 Reduced 34.93%
45,270 $4.34 Million
Q3 2018

Nov 08, 2018

SELL
$138.11 - $169.04 $13,811 - $16,904
-100 Reduced 0.14%
69,570 $9.83 Million
Q2 2018

Aug 13, 2018

BUY
$140.36 - $175.76 $937,043 - $1.17 Million
6,676 Added 10.6%
69,670 $10.9 Million
Q1 2018

May 14, 2018

BUY
$152.15 - $192.33 $2.72 Million - $3.44 Million
17,874 Added 39.61%
62,994 $10.1 Million
Q4 2017

Feb 13, 2018

SELL
$60.72 - $167.34 $81,607 - $224,904
-1,344 Reduced 2.89%
45,120 $7.43 Million
Q3 2017

Nov 13, 2017

BUY
$61.4 - $88.52 $2.85 Million - $4.11 Million
46,464
46,464 $2.9 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $428M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.